Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjin Fuyan Pian is a Traditional Chinese Medicine (TCM) formulation developed by Guilin Sanjin Pharmaceutical for the treatment of chronic pelvic inflammatory disease (CPID). It is specifically indicated for patients presenting with the 'damp-heat and blood stasis' syndrome, a common TCM diagnostic pattern for CPID. The drug is composed of multiple herbal extracts intended to clear heat, detoxify, remove dampness, and promote blood circulation to resolve stasis. Clinical evaluation, including Phase III trials in China, has focused on its ability to reduce pelvic pain, improve clinical symptoms, and ensure safety in the long-term management of gynecological inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanjin Fuyan Pian.